Arcus Biosciences is a clinical-stage biopharmaceutical company focused on
creating innovative cancer immunotherapies. Arcus has several programs
targeting important immuno-oncology pathways, including a dual adenosine
receptor antagonist AB928, which is in a Phase 1/1b program to evaluate
AB928 in combination with other agents in multiple tumor types, and an
anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and
is being tested in combination with Arcus’s other product candidates.
Arcus’s other programs include AB154, an anti-TIGIT antibody, which is in a
Phase 1 trial to evaluate AB154 as monotherapy and in combination with
AB122, and AB680, a small molecule inhibitor of CD73, which is in
IND-enabling studies. Arcus has extensive in-house expertise in medicinal
chemistry, immunology, biochemistry, pharmacology and structural biology.